IP Position around SYGNIS’ AX200 significantly strengthened
“This decision by the USPTO strengthens our position in the world’s largest pharmaceutical market and confirms our strategy of increasing the commercial potential of our compounds through broadened patent protection. We look forward to continuing the development of AX200 in acute ischemic stroke with the forthcoming initiation of our planned phase II efficacy trial” said Dr. Alfred Bach, CEO of SYGNIS.
In June 2006, SYGNIS exclusively licensed the respective global rights to this patent application from the Max-Planck Gesellschaft. The corresponding European patent was already granted by the European Patent Office in 2004.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.